济南前列腺 病因济南有什么办法更持久,济南前列腺增生能治好吗,济南近男科医院,济南如何治疗泌尿性感染,济南前列腺炎应怎么治疗,济南射得很快,济南射精一般多长时间

HAVANA, Sept. 6 (Xinhua) -- Cuban medical authorities have launched the sales of the world's first therapeutic vaccine against lung cancer, local officials said on Tuesday.The CimaVax-EGF vaccine, as a result of a 25-year research into diseases related to tobacco smoking, has been developed by researchers and scientists at the Center of Molecular Immunology (CIM) in Havana.The active drug ingredient in the vaccine is based on "a protein we all have when cancer is uncontrolled." "The epidermal growth factor is related to all cell proliferation," said Gisela Gonzalez, head researcher of the project."The drug could turn the cancer into a manageable, chronic disease by generating antibodies against the proteins which triggered the uncontrolled cell proliferation," she said.The immunogenic vaccine is appropriate to patients with advanced lung cancer in stages of three and four, showing no positive response to other kinds of treatments such as chemotherapy and radiotherapy, the expert said."It is not possible to prevent the disease but this vaccine improves significantly the status of the critically ill patients," she added.She said the CimaVax-EGF has gone through clinical studies and trials in over 1,000 patients across the island and is currently distributed free of charge in all hospitals of the Caribbean island nation.Gonzalez also said researchers at the CIM planned to use the same principle of the CimaVax-EGF in treating other cancerous tumors such as prostate, uterus and breast cancers.Lung cancer is regarded as one of the world's most serious, common and deadly cancers and is most frequently found among tobacco smokers.According to the World Health Organization, the disease generally kills 5 million people a year, and the figure is expected to rise to as much as 8 million by 2030 unless smoking habits are changed.In Cuba, like many other developing countries across the world, smoking is seen as a status symbol. Lung cancer, killing about 20,000 people a year in the Caribbean country, is considered a serious threat to public health and the leading cause of death in 12 of the country's 15 provinces.

NEW YORK, July 15 (Xinhua) -- A Gallup survey released on Friday found a total of 59 percent of Americans support a ban on smoking in all public places.The July 7-10 survey among 1,016 national adults showed a change in the public's attitude toward public smoking ban. In 2001, when Gallup first asked about a ban on public smoking, 39 percent were in favor, an attitude that stayed roughly the same through 2007.At the same time, the poll also found that fewer than two in 10 people supported the idea of making smoking totally illegal.According to the American Lung Association, 27 states plus the District of Columbia have passed comprehensive smoke-free laws. A New York City law bans smoking in virtually all public places, including outdoor plazas and beaches.

SINGAPORE, Sept. 7 (Xinhua) -- Singapore scientists have found possible new ways to treat a type of aggressive breast cancer that is unresponsive to current forms of treatment, local broadcaster Channel NewsAsia reported on Wednesday.The team of scientists at the Genome Institute of Singapore ( GIS) and National University of Singapore (NUS), led by GIS senior group leader Qiang Yu, found that the enzyme EZH2 acts by inhibiting genes that stop the growth of tumors in the body.The insights could open the door to developing more effective treatment for fast spreading breast cancers, especially the estrogen receptor-negative breast cancer that is common all over the world.It was also found that through EZH2, cancer is promoted in the body by activating specific genes that impact breast cancer progression and cancer stem cell self-renewal.Yu said the new understanding on how EZH2 works as a cancer- causing gene in breast cancer has important therapeutic implication."The results suggest that small molecule drugs that block enzyme activity of EZH2 may not work for cancers caused by EZH2's activation genes," Yu said.Currently pharmaceutical companies have been developing drugs only to the block EZH2 enzyme activity so that tumor suppressers can perform their protective role in blocking cancer growth.Researchers said the next step would be to develop biomarkers to identify tumors with EZH2.This step would enable better treatment methods, with one of options being the development of therapies that shut down EZH2 completely and not just inhibit its enzymatic function.The findings have been published on the journal Molecular Cell.

BEIJING, Sept. 20 (Xinhua) -- Floods and landslides triggered by recent heavy rains in eight of China's provincial-level regions have left 70 people dead and 32 others missing this month.Heavy downpours, floods and other related disasters have affected Sichuan, Shaanxi, Henan, Chongqing, Hubei, Shandong, Shanxi and Gansu, the National Disaster Reduction Commission said in a statement released on Tuesday.As of Tuesday, these disasters have affected 21.56 million people and caused an estimated 26.09 billion yuan (4.08 billion U.S. dollars) in direct economic losses, the statement said.

BEIJING, Sept. 28 (Xinhuanet) -- The unmanned Shenzhou VIII, part of China's first spacecraft rendezvous and docking mission, will be launched in early November. Niu Hongguang, deputy commander-in-chief of the program, said on Tuesday the launch has not been affected by the postponed lift-off of the Tiangong-1 space module. Tiangong-1 was to enter a low orbit around Earth at the end of August before being met by Shenzhou VIII. However, the departure was pushed back after a satellite failure on Aug 18. Out of safety concerns, Niu said mission commanders ordered a halt to testing at Jiuquan Satellite Launch Center on Tiangong-1 and its carrier rocket, Long March II-F T1. China Aerospace Science and Technology Corp, which designed and made the rocket carrier that failed to launch, formed an expert panel to investigate and made modifications. A successful launch of a communication satellite on Sept 19 using the Long March II-C showed the measures worked, Niu said, adding: "We now have confidence in the launch of Tiangong-1." The module is a "simplified" space lab that will not only be a docking target, but will also work as a space experimental platform. It will be unmanned for most of its two years of use, although astronauts will spend time onboard for short periods. After Shenzhou VIII, the country will launch Shenzhou IX and Shenzhou X next year to rendezvous and dock with Tiangong-1. Niu confirmed Shenzhou X will be manned. Tiangong-1 can accommodate two to three astronauts. "Whether Shenzhou IX will be manned is up to the results of the first rendezvous and docking mission," he said. The rocket carrier with Tiangong-1 atop stands 52 meters tall, with a takeoff weight of 493 tons. Tiangong-1 was scheduled for launch in between Sept 27 and 30, but due to weather forecasts that predicted a cold air mass would move into the area of Jiuquan Satellite Launch Center, it is believed that conditions on Thursday and Friday will be suitable for takeoff.